Ziftomenib Elicits Responses in Relapsed/Refractory AML Mutation Subgroups

News
Video

At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .

The rate of complete remissions (CR) that occurred following treatment with ziftomenib in patients with NPM1-mutated relapsed/refractory acute myeloid leukemia were a point of interest, as half were also minimal residual disease (MRD) negative, according to Harry Erba, MD.

Erba, a hematologic oncologist at Duke Health, interviewed with CancerNetwork® regarding these findings, which read out as part of the phase 1/2 KOMET-001 trial (NCT04067336).

Transcript:

We had a cohort of 20 patients with NPM1 mutated relapsed/refractory acute myeloid leukemia who were treated with ziftomenib at 600 mg daily. In that population of patients from the phase 1a/1b portion of the study, we saw complete remissions (CR) with full blood count recovery and another patient with a CRi [incomplete hematologic response].

What was interesting is that by local criteria, about half of those remissions were MRD negative. The other thing that was very interesting is that 2 of the patients had concurrent IDH1 and IDH2 mutations and 2 patients had both IDH mutation and a FLT3-ITD or TKD, and were in the complete response group.

On the other hand, we saw a signal for increased differentiation syndrome in the KMT2A-rearrange patients at both the 200 mg and 600 mg doses with only 1 CR in the KMT2A-rearranged patients of the 32 who were treated in the study.

We believe this was due to the early discontinuation of ziftomenib that was due to investigators taking their patients off study treatment due to a rapidly rising white blood cell count or the development of extramedullary disease. In retrospect, we think that many of these patients likely had an exuberant differentiation syndrome, causing the blast increase, as well as this proliferation or increase in extramedullary disease.

For example, in one of my patients for whom I was able to continue the study drug, each of those sites of extramedullary disease went away with continued treatment with ziftomenib without any other antileukemic effect.

We believe that we are seeing this signal for differentiation syndrome and the extramedullary apparent progression of disease due to differentiation because of the high tissue penetration of ziftomenib. [Additionally], patients with KMT2A rearranged AML often have monocytic morphology and a high incidence of extramedullary disease, either clinically or obvious or subclass.

Reference

Erba HP, Fathi AT, Issa GC, et al. Update on a phase 1/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022; 140(suppl 1):153-156. doi:10.1182/blood-2022-167412

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Related Content
Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Olutasidenib Yields Enduring Remissions in Previously Treated IDH1+ AML

April 12th 2024
Article

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.

Novel CDK9 Inhibitor Yields Responses in Relapsed/Refractory AML

March 29th 2024
Article

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Study authors note that access to multidisciplinary teams and transportation programs may help mitigate hematopoietic cell transplantation outcome disparities.

No Major Racial Disparities Reported in Allogeneic Transplant Outcomes

March 20th 2024
Article

Study authors note that access to multidisciplinary teams and transportation programs may help mitigate hematopoietic cell transplantation outcome disparities.

Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

FDA Grants Accelerated Approval to Ponatinib Combo in Ph+ ALL

March 19th 2024
Article

Data from the phase 3 PhALLCON trial support the FDA accelerated approval of ponatinib plus chemotherapy in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.